Financials data is unavailable for this security.
View more
Year on year Crinetics Pharmaceuticals Inc 's revenues fell -15.28% from 4.74m to 4.01m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 163.92m to a larger loss of 214.53m.
Gross margin | -- |
---|---|
Net profit margin | -18,257.91% |
Operating margin | -20,068.38% |
Return on assets | -41.16% |
---|---|
Return on equity | -47.66% |
Return on investment | -44.29% |
More ▼
Cash flow in USDView more
In 2023, Crinetics Pharmaceuticals Inc increased its cash reserves by 65.42%, or 22.22m. Cash Flow from Financing totalled 388.94m or 9,692.10% of revenues. In addition the company used 166.31m for operations while cash used for investing totalled 200.41m.
Cash flow per share | -3.65 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.47 |
---|---|
Tangible book value per share | 10.47 |
More ▼
Balance sheet in USDView more
Current ratio | 16.09 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼